Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/183178
Title: | Nationwide COVID-19-EII Study: Incidence, Environmental Risk Factors and Long-Term Follow-Up of Patients with Inflammatory Bowel Disease and COVID-19 of the ENEIDA Registry |
Author: | Zabana, Yamile Esteve i Comas, Maria Caballol, Berta Suris, Gerard Ricart, Elena on behalf of the ENEIDA registry of GETECCU |
Keywords: | COVID-19 Factors de risc en les malalties SARS-CoV-2 Pronòstic mèdic COVID-19 Risk factors in diseases SARS-CoV-2 Prognosis |
Issue Date: | 14-Jan-2022 |
Publisher: | MDPI |
Abstract: | We aim to describe the incidence and source of contagion of COVID-19 in patients with IBD, as well as the risk factors for a severe course and long-term sequelae. This is a prospective observational study of IBD and COVID-19 included in the ENEIDA registry (53,682 from 73 centres) between March-July 2020 followed-up for 12 months. Results were compared with data of the general population (National Centre of Epidemiology and Catalonia). A total of 482 patients with COVID-19 were identified. Twenty-eight percent were infected in the work environment, and 48% were infected by intrafamilial transmission, despite having good adherence to lockdown. Thirty-five percent required hospitalization, 7.9% had severe COVID-19 and 3.7% died. Similar data were reported in the general population (hospitalisation 19.5%, ICU 2.1% and mortality 4.6%). Factors related to death and severe COVID-19 were being aged ≥ 60 years (OR 7.1, 95% CI: 1.8-27 and 4.5, 95% CI: 1.3-15.9), while having ≥2 comorbidities increased mortality (OR 3.9, 95% CI: 1.3-11.6). None of the drugs for IBD were related to severe COVID-19. Immunosuppression was definitively stopped in 1% of patients at 12 months. The prognosis of COVID-19 in IBD, even in immunosuppressed patients, is similar to that in the general population. Thus, there is no need for more strict protection measures in IBD. |
Note: | Reproducció del document publicat a: https://doi.org/10.3390/jcm11020421 |
It is part of: | Journal of Clinical Medicine, 2022, vol. 11, num. 2, p. 421 |
URI: | http://hdl.handle.net/2445/183178 |
Related resource: | https://doi.org/10.3390/jcm11020421 |
ISSN: | 2077-0383 |
Appears in Collections: | Articles publicats en revistes (Medicina) Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer) Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
717749.pdf | 1.06 MB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License